traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone
Company profile
Ticker
EYEG, KPRX
Exchange
Website
CEO
Stephen From
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
EYEGATE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Jade Therapeutics, Inc. • Kiora Pharmaceuticals GmbH • Bayon Therapeutics, Inc. • Kiora Pharmaceuticals Pty Ltd ...
EYEG stock data
Latest filings (excl ownership)
8-K
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
9 Aug 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
8-K
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
30 Jul 24
8-K
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
1 Jul 24
8-K
Material Modifications to Rights of Security Holders
7 Jun 24
8-K
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
10 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
S-8
Registration of securities for employees
10 May 24
EFFECT
Notice of effectiveness
29 Mar 24
424B3
Prospectus supplement
28 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.58 mm | 6.58 mm | 6.58 mm | 6.58 mm | 6.58 mm | 6.58 mm |
Cash burn (monthly) | 8.23 mm | 114.69 k | 848.30 k | (no burn) | 1.24 mm | (no burn) |
Cash used (since last report) | 30.92 mm | 430.65 k | 3.19 mm | n/a | 4.67 mm | n/a |
Cash remaining | -24.34 mm | 6.15 mm | 3.39 mm | n/a | 1.91 mm | n/a |
Runway (months of cash) | -3.0 | 53.6 | 4.0 | n/a | 1.5 | n/a |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 15 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.06 bn |
Total shares | 8.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 3.47 mm | $519.00 k |
Lincoln Park Capital Fund | 3.28 mm | $491.00 k |
Lind Global Fund II | 345.51 k | $269.00 k |
Bigger Capital Fund L P | 289.54 k | $437.00 k |
AIGH Capital Management | 255.56 k | $1.07 bn |
Nantahala Capital Management | 211.11 k | $886.66 mm |
Alyeska Investment | 180.78 k | $759.28 mm |
ADAR1 Capital Management | 172.60 k | $724.90 mm |
Velan Capital Investment Management | 122.22 k | $513.34 mm |
Geode Capital Management | 13.77 k | $57.84 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Sep 24 | Carmine N. Stengone | Common Stock | Buy | Acquire P | No | No | 3.68 | 1,250 | 4.60 k | 1,250 |
10 Sep 24 | Aron Shapiro | Common Stock | Buy | Acquire P | Yes | No | 3.6 | 3,000 | 10.80 k | 3,000 |
19 Aug 24 | Praveen Tyle | Common Stock | Buy | Acquire P | No | No | 3.96 | 5,000 | 19.80 k | 5,014 |
19 Aug 24 | Walters-Hoffert Lisa | Common Stock | Buy | Acquire P | No | No | 3.86 | 1,250 | 4.83 k | 1,250 |
14 Aug 24 | Melissa Tosca | Common Stock | Buy | Acquire P | No | No | 3.21 | 2,000 | 6.42 k | 13,599 |